长效肽设计 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-12. Anything still debated is marked as such rather than presented as settled.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
In anticipation of the talks, Pakistan military's Inter-Services Intelligence had sent out a private message on WhatsApp to reporters stating that Araghchi was visiting Islamabad and would meet his american counterparts as "Attributable to Government Sources." Araghchi never went to Islamabad to re-open talks and did not be meet with Witkoff and Kushner as was anticipated. Trump had to call off the trip, saying the Iranians could phone them if they wanted. In May, anonymous US officials revealed to CBS News that during the initial ceasefire period in early April, Pakistan covertly allowed Iranian military aircraft, including the RC-130, to park on its airfields, including Nur Khan airbase, potentially shielding them from American airstrikes. Trump administration officials also expressed their suspicions that Pakistan was sharing "a more positive version of the Iranian position with the US than what reflects reality" while questioning whether "Trump’s displeasure" was being communicated as aggressively. On 17 June 2026, the Islamabad Memorandum was signed remotely between the presidents of the US, Donald Trump, and Iran, Masoud Pezeshkian. The memorandum is a 14-point "framework agreement" and provides for an end to military strikes, the reopening of the Strait of Hormuz to commercial shipping toll-free for 60 days, an end to the U.S. naval blockade of Iranian ports, and a 60-day extension of the ceasefire. The memorandum also includes a $300 billion fund for Iran in addition to the release of frozen Iranian assets, as well as sanctions relief.
== History == In 1988, Stark introduced an "Ethics in Patient Referrals" bill concerning physician self-referrals. Some of the ideas in the bill became law as part of the Omnibus Budget Reconciliation Act of 1990. In specific, what is referred to as "Stark I" prohibited a physician referring a Medicare patient to a clinical laboratory if the physician or his/her family member has a financial interest in that laboratory. It was codified in the United States Code, Title 42, Section 1395nn (42 U.S.C. 1395nn, "Limitation on certain physician referrals"). The Omnibus Budget Reconciliation Act of 1993 contained what is known as "Stark II" amendments to the original law. "Stark II" extended the "Stark I" provisions to Medicaid patients and to DHS other than clinical laboratory services. The Centers for Medicare and Medicaid Services has issued rules in the Federal Register to implement Stark Law, including a 2001 "Phase I" final rule, a 2004 "Phase II" interim final rule, and a 2007 "Phase III" final rule.
In MCCs, there is no deconvolution required to determine which compounds are biologically active, because each synthesis in an array has only a single product, thus the identity of the compound should be unequivocally known.
Two isolated fossilized footprints have been tentatively assigned to T. rex. The first was discovered at Philmont Scout Ranch, New Mexico, in 1983 by American geologist Charles Pillmore. Originally thought to belong to a hadrosaurid, examination of the footprint revealed a large 'heel' unknown in ornithopod dinosaur tracks, and traces of what may have been a hallux, the dewclaw-like fourth digit of the tyrannosaur foot. The footprint was published as the ichnogenus Tyrannosauripus pillmorei in 1994, by Martin Lockley and Adrian Hunt. Lockley and Hunt suggested that it was very likely the track was made by a T. rex, which would make it the first known footprint from this species. The track was made in what was once a vegetated wetland mudflat. It measures 83 centimeters (33 in) long by 71 centimeters (28 in) wide. A second footprint that may have been made by a Tyrannosaurus was first reported in 2007 by British paleontologist Phil Manning, from the Hell Creek Formation of Montana. This second track measures 72 centimeters (28 in) long, shorter than the track described by Lockley and Hunt. Whether or not the track was made by Tyrannosaurus is unclear, though Tyrannosaurus is the only large theropod known to have existed in the Hell Creek Formation. A set of footprints in Glenrock, Wyoming dating to the Maastrichtian stage of the Late Cretaceous and hailing from the Lance Formation were described by Scott Persons, Phil Currie and colleagues in 2016, and are believed to belong to either a juvenile T. rex or Nanotyrannus lancensis.
Glutamate-cysteine ligase regulatory subunit is an enzyme that in humans is encoded by the GCLM gene. Glutamate-cysteine ligase, also known as gamma-glutamylcysteine synthetase, is the first rate limiting enzyme of glutathione synthesis. The enzyme consists of two subunits, a heavy catalytic subunit and a light regulatory subunit. Gamma glutamylcysteine synthetase deficiency has been implicated in some forms of hemolytic anemia.
Sources: en.wikipedia.org
Raines (born 1958), chemical biologist and expert on the chemistry and biology of proteins Mark SaFranko, writer, playwright and actor Kenneth B. Smith (1931–2008), President of the Board of Education of the Chicago Public Schools who also served as President of the Chicago Theological Seminary Leo Sternbach (1908–2005), chemist, invented precursor to Valium Bruce Wands (1949–2022), educator, author, artist, and musician, with a specific interest in digital art Edward Weston (1850–1936), electrical engineer and inventor whose Weston Electrical Instrument Company won the contract to illuminate the Brooklyn Bridge
Evidence from the study of carbon and oxygen isotope composition of tooth enamel of equids, bovids and hippopotamids from Melka Wakena and Gadeb, interpreted as indicative of presence of montane grasslands with shrubs and aquatic habitats in Ethiopian highlands that provided recurrent access to water and vegetation to mammals (including Acheulean-making hominins) in the late Early Pleistocene, is presented by Briatico et al. (2026). Evidence from the study of the composition of Middle and Late Pleistocene small mammalian assemblages from the East European Plain, interpreted as consistent with presence of semi-arid and arid steppe habitats during the warmest and driest phases of the Pleistocene interglacials, is presented Markova, Puzachenko & Tsatskin (2026). Robu et al. (2026) reconstruct trophic relationships of Late Pleistocene mammals from cave sites in the Romanian Carpathians with and without bears on the basis of an isotopic analysis of their bones, reporting evidence of overall similar dietary behavior of the studied mammals throughout Europe during Marine Isotope Stage 3, as well as evidence of mainly herbivorous diet of cave bears that included varying levels of animal protein consumption, and interpret the dietary behavior of the studied cave bears as possibly influenced by abundance of the carnivores. Russo et al. (2026) study the composition of Pleistocene faunal assemblages from the Naame, Nahr Ibrahim and Ras el-Kelb sites (Lebanon) and tooth wear of ungulates from these sites, while Russo et al.
Measurement tools, such as goniometers and inclinometers, aid in standardized quantification of joint motion relative to normative values or ranges. Tests that follow functional movements, such as reaching overhead, squatting, or rotating the neck, are used to evaluate whether reduced ROM translates into activity limitation. When hypomobility is regional, clinicians can use condition-specific values to compare the patient's ROM values against. For instance, in the shoulder, adhesive capsulitis (frozen shoulder) is defined by marked loss of both active and passive motion (particularly external rotation and abduction). For the knee, postoperative arthrofibrosis is typically diagnosed when extension loss exceeds 10° or flexion is limited to less than 100°, with more severe forms showing a flexion deficit of 25° or greater. In the spine, decreased ROM is assessed using values developed for ankylosing spondylitis and related disorders. The Modified Schober Test measures lumbar flexion. An increase of less than 5 cm indicates limited motion, chest expansion of 2.5 cm or less suggests thoracic restriction, and an occiput-to-wall distance greater than 2 cm shows thoracic or cervical extension limitation. The Bath Ankylosing Spondylitis Metrology Index (BASMI) provides a composite score summarizing these spinal mobility measures and is widely used to quantify skeletal hypomobility.
=== General mechanism === In acidic conditions, ptaquiloside gradually undergoes aromatization with the elimination of D-glucose to afford ptaquilosin, and finally pterosin B. Under weakly alkaline conditions, ptaquiloside and its aglycone ptaquilosin are converted into an unstable conjugated dienone intermediate. This ptaquilodienone is the activated form of ptaquiloside and is regarded as the ultimate carcinogen of bracken ferns. Due to the constitution of a cyclopropyl carbinol system, ptaquilodienone is a strong electrophile and acts as a powerful alkylating agent that reacts directly with biological nucleophiles including amino acids, nucleosides, and nucleotides under weakly acidic conditions at room temperature (as shown in the scheme below).
The first Masons in Cuba were most likely Speculative and Operative, not Symbolic, and arrived by the early half of the 18th Century, as indicated by archaeological evidences of Masonic symbols that were found carved into the stones of the Convent of San Francisco as Mason's marks, which have been relatively dated to its current construction beginning in 1716, the year before Symbolic Freemasonry was established in England. These symbols were carved by operative stonemasons who had been brought into the country by the Catholic Church from disparate parts of the European continent to work on the construction project. At that time, Operative Masonic and Speculative Masonic guilds in Spain were not centralized, functioning instead as independent and unique Lodges, and it was not until 1728 that they formed the unified body of Freemasonry in Spain. The Convent of San Francisco did also receive renovations in 1731, but Havana's official City Historian, Eusebio Leal Spengler, stated during an inspection of the site that the marks were part of the construction of the convent and were not added anytime after the first half of the 18th Century. In 1738, ten years after Symbolic Freemasonry arrived in Spain, Pope Clement XII issued a Papal bull banning the practice of Freemasonry in the Catholic church. Following this, the Grand Inquisitor of Spain issued an edict banning the practice within the Spanish church by punishment of excommunication and a fine. In 1750, José Torrubia, while working for the Holy Office of the Inquisition in Madrid, went undercover as a Freemason in Spain.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.